Abstract
Activating Ras mutations are associated with ~30% of all human cancers, which often respond poorly to standard therapies. The four Ras isoforms are therefore highly attractive targets for anticancer drug discovery. However, Ras proteins function through protein-protein interactions and their surfaces lack any major pockets for small molecules to bind; as a result they have been declared “undruggable” for the past 30 years. Several breakthroughs during the past few years may finally remove Ras from the list of undruggable proteins. This mini-review discusses the current approaches to developing inhibitors especially cyclic peptides that physically block the interaction between Ras and its downstream effector proteins, which is potentially the most effective approach for treating Ras mutant cancers.
Keywords: Cancer, Cell signaling, Inhibition, Macrocycles, Protein-protein interaction, Ras.
Mini-Reviews in Medicinal Chemistry
Title:Direct Inhibitors of Ras-Effector Protein Interactions
Volume: 16 Issue: 5
Author(s): Punit Upadhyaya, Walaa Bedewy and Dehua Pei
Affiliation:
Keywords: Cancer, Cell signaling, Inhibition, Macrocycles, Protein-protein interaction, Ras.
Abstract: Activating Ras mutations are associated with ~30% of all human cancers, which often respond poorly to standard therapies. The four Ras isoforms are therefore highly attractive targets for anticancer drug discovery. However, Ras proteins function through protein-protein interactions and their surfaces lack any major pockets for small molecules to bind; as a result they have been declared “undruggable” for the past 30 years. Several breakthroughs during the past few years may finally remove Ras from the list of undruggable proteins. This mini-review discusses the current approaches to developing inhibitors especially cyclic peptides that physically block the interaction between Ras and its downstream effector proteins, which is potentially the most effective approach for treating Ras mutant cancers.
Export Options
About this article
Cite this article as:
Upadhyaya Punit, Bedewy Walaa and Pei Dehua, Direct Inhibitors of Ras-Effector Protein Interactions, Mini-Reviews in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1389557515666151001141713
DOI https://dx.doi.org/10.2174/1389557515666151001141713 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview
Current Pharmaceutical Design Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM
Current Cancer Drug Targets Meet Our Editorial Board Member
Current Enzyme Inhibition Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications
Current Topics in Medicinal Chemistry Robust Pulmonary Nodule Segmentation in CT Image for Juxta-pleural and Juxta-vascular Case
Current Bioinformatics Proteomic and Glycomic Markers to Differentiate Lung Adenocarcinoma from COPD
Current Medicinal Chemistry Salivary Genomics, Transcriptomics and Proteomics: The Emerging Concept of the Oral Ecosystem and their Use in the Early Diagnosis of Cancer and other Diseases
Current Genomics Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Lycorine and its Derivatives for Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry A Classification Method for Microarrays Based on Diversity
Current Bioinformatics Mutagenesis by Environmental Pollutants and Bio-Monitoring of Environmental Mutagens
Current Drug Metabolism Editorial [Hot Topic: Beyond Chemotherapy: Future Directions in Lymphoma Treatment (Guest Editor: Thomas Decker)]
Current Drug Targets The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery Editorial
Recent Patents on Anti-Cancer Drug Discovery uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Tumor Promoters - Microcystin-LR, Nodularin and TNF-α and Human Cancer Development
Anti-Cancer Agents in Medicinal Chemistry